Type 2 Diabetes Trial, Recruiting (NCT06902077)

Type 2 Diabetes Trial, Recruiting NCT06902077 Sponsor: University of Alabama at Birmingham Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06902077 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 12 and 18 years old
You have been diagnosed with diabetes for more than 3 months
Your average blood sugar level (HbA1c) is between 6.5% and 8.5%
Your BMI is above the 85th percentile for your age (meaning you are in a higher weight range compared to others your age)
A blood test has shown that your immune system is not attacking your pancreas (negative pancreatic autoantibodies)
You have been on a stable dose of certain diabetes medications (such as GLP-1, metformin, or SGLT-2 inhibitors) for at least 3 months

Who may not be able to join:

You are currently using insulin to manage your diabetes
Your kidneys are not working fully as shown by a specific blood test result (confirm with trial site)
Your liver is not working fully as shown by elevated liver enzyme levels on a blood test (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ortal Resnick, MD, University of Alabama at Birmingham

Phone: 205-638-9107

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06902077

Sponsor: University of Alabama at Birmingham

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: 205-638-9107

More information: https://clinicaltrials.gov/study/NCT06902077

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 12 and 18 years old
You have been diagnosed with diabetes for more than 3 months
Your average blood sugar level (HbA1c) is between 6.5% and 8.5%
Your BMI is above the 85th percentile for your age (meaning you are in a higher weight range compared to others your age)
A blood test has shown that your immune system is not attacking your pancreas (negative pancreatic autoantibodies)
You have been on a stable dose of certain diabetes medications (such as GLP-1, metformin, or SGLT-2 inhibitors) for at least 3 months

Who may not be able to join:

You are currently using insulin to manage your diabetes
Your kidneys are not working fully as shown by a specific blood test result (confirm with trial site)
Your liver is not working fully as shown by elevated liver enzyme levels on a blood test (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Alabama at Birmingham

Registry

ClinicalTrials.gov

Start date

25 November 2025

Est. completion

31 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in HbA1c; Homeostatic Model Assessment of Insulin Resistance (HOMA-IR); Whole Body Insulin Sensitivity Index (WBISI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov